AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal
By Jade Martinez-Pogue · August 25, 2025, 3:21 PM EDT
Covington & Burling LLP-advised biotech company AbbVie on Monday announced plans to acquire Ropes & Gray LLP-led Gilgamesh Pharmaceuticals' lead investigational candidate, which targets the treatment of patients with moderate to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login